SuPerficially inConspicuous Problem – urinary tract infection at PCP office Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
urinary tract infection, fosfomycin, multidrug resistance
Main Article Content
Abstract
Urinary tract infection is one of the most common situations in the family doctor where antibiotics are recommended. This article discusses groups of patients for whom, based on current reports, fosfomycin has been used for many years. The potential application of this antibiotic in the case of urinary tract infections with multidrug-resistant pathogens was also presented.
Article Details
How to Cite
Adamska-Wełnicka , A. (2021). SuPerficially inConspicuous Problem – urinary tract infection at PCP office. Medycyna Faktow (J EBM), 14(3(52), 246-249. https://doi.org/10.24292/01.MF.0321.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012; 366(11): 1028-37. http://doi.org/10.1056/NEJMcp1104429.
2. Hryniewicz W, Holecki M (ed). Rekomendacje diagnostyki, terapii i profilaktyki zakażeń układu moczowego u dorosłych. Narodowy Instytut Leków, Warszawa 2015.
3. Stamm WE, McKevitt M, Roberts PL et al. Natural history of recurrent urinary tract infections in women. Rev Infect Dis. 1991; 13(1): 77-84. http://doi.org/10.1093/clinids/13.1.77.
4. Nicolle LE, Gupta K, Bradley SF et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019; 68(10): e83-e110. http://doi.org/10.1093/cid/ciy1121.
5. Żukowska A, Hryniewicz W (ed). Rekomendacje diagnostyki, terapii i profilaktyki antybiotykowej zakażeń w szpitalu – 2020. Narodowy Instytut Leków, Warszawa 2020.
6. World Health Organization. Antimicrobial resistance: Global Report on Surveillance. 2014 (access: 1.09.2021).
7. Coates ARM, Hu Y, Holt J et al. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther. 2020; 18(1): 5-15. http://doi.org/10.1080/14787210.2020.1705155.
8. Naber KG, Schito G, Botto H et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008; 54(5): 1164-75. http://doi.org/10.1016/j.eururo.2008.05.010.
9. Urinary tract infections (recurrent) antimicrobial prescribing. NICE guideline 2018 (access: 1.09.2021).
10. Bonkat G, Bartoletti R, Bruyere F et al. EAU Guidelines on urological infections. European Association of Urology 2019.
11. Falagas ME, Kastoris AC, Kapaskelis AM et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1): 43-50. http://doi.org/10.1016/S1473-3099(09)70325-1.
12. Maraki S, Samonis G, Rafailidis PI et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009; 53(10): 4508-10. http://doi.org/10.1128/AAC.00721-09.
13. Patwardhan V, Singh S. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully. Int Urol Nephrol. 2017; 49(9): 1637-43. http://doi.org/10.1007/s11255-017-1627-6.
14. Endimiani A, Patel G, Hujer KM et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010; 54(1): 526-9. http://doi.org/10.1128/AAC.01235-09.
15. Hryniewicz W, Żabicka D. Stanowisko Zespołu Roboczego ds. oznaczania lekowrażliwości zgodnie z zaleceniami EUCAST w sprawie najczęściej zgłaszanych pytań dotyczących stosowania rekomendacji EUCAST wersja 4.0, 1 maja 2020.
16. Nwabor OF, Terbtothakun P, Voravuthikunchai SP et al. Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii. Pharmaceuticals (Basel). 2021; 14(3): 185. http://doi.org/10.3390/ph14030185.
2. Hryniewicz W, Holecki M (ed). Rekomendacje diagnostyki, terapii i profilaktyki zakażeń układu moczowego u dorosłych. Narodowy Instytut Leków, Warszawa 2015.
3. Stamm WE, McKevitt M, Roberts PL et al. Natural history of recurrent urinary tract infections in women. Rev Infect Dis. 1991; 13(1): 77-84. http://doi.org/10.1093/clinids/13.1.77.
4. Nicolle LE, Gupta K, Bradley SF et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019; 68(10): e83-e110. http://doi.org/10.1093/cid/ciy1121.
5. Żukowska A, Hryniewicz W (ed). Rekomendacje diagnostyki, terapii i profilaktyki antybiotykowej zakażeń w szpitalu – 2020. Narodowy Instytut Leków, Warszawa 2020.
6. World Health Organization. Antimicrobial resistance: Global Report on Surveillance. 2014 (access: 1.09.2021).
7. Coates ARM, Hu Y, Holt J et al. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther. 2020; 18(1): 5-15. http://doi.org/10.1080/14787210.2020.1705155.
8. Naber KG, Schito G, Botto H et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008; 54(5): 1164-75. http://doi.org/10.1016/j.eururo.2008.05.010.
9. Urinary tract infections (recurrent) antimicrobial prescribing. NICE guideline 2018 (access: 1.09.2021).
10. Bonkat G, Bartoletti R, Bruyere F et al. EAU Guidelines on urological infections. European Association of Urology 2019.
11. Falagas ME, Kastoris AC, Kapaskelis AM et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1): 43-50. http://doi.org/10.1016/S1473-3099(09)70325-1.
12. Maraki S, Samonis G, Rafailidis PI et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009; 53(10): 4508-10. http://doi.org/10.1128/AAC.00721-09.
13. Patwardhan V, Singh S. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully. Int Urol Nephrol. 2017; 49(9): 1637-43. http://doi.org/10.1007/s11255-017-1627-6.
14. Endimiani A, Patel G, Hujer KM et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010; 54(1): 526-9. http://doi.org/10.1128/AAC.01235-09.
15. Hryniewicz W, Żabicka D. Stanowisko Zespołu Roboczego ds. oznaczania lekowrażliwości zgodnie z zaleceniami EUCAST w sprawie najczęściej zgłaszanych pytań dotyczących stosowania rekomendacji EUCAST wersja 4.0, 1 maja 2020.
16. Nwabor OF, Terbtothakun P, Voravuthikunchai SP et al. Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii. Pharmaceuticals (Basel). 2021; 14(3): 185. http://doi.org/10.3390/ph14030185.